RSV Vaccine Maintains Efficacy Across Two Seasons in Seniors
BOSTON — Efficacy of GSK’s respiratory syncytial virus (RSV) vaccine held strong through two RSV seasons in adults 60 and over, according to new results from the company’s pivotal trial. With a single dose, efficacy of the RSV perfusion F protein vaccine (Arexvy) against RSV-related lower respiratory tract disease declined from 82.6% during the first […]
CDC Advisors Endorse Maternal RSV Vax to Protect Newborns
The CDC’s advisors on Friday recommended a maternal respiratory syncytial virus (RSV) vaccine to protect infants from serious infections. By an 11-1 vote, the Advisory Committee on Immunization Practices (ACIP) recommended that pregnant women receive a single dose of Pfizer’s prefusion F protein (RSVpreF) vaccine (Abrysvo) at 32 to 36 weeks’ gestation to prevent lower […]
ERS Roundup: Cell Transplant Boosts Lung Function in COPD Patients
MILAN — Research presented at this year’s annual European Respiratory Society congress included early successes in transplanting a patient’s own lung cells to ease chronic obstructive pulmonary disease (COPD), idrevloride treatment for primary ciliary dyskinesia, and using ultrasounds as a guide for more comprehensive pulmonary embolism screening. Improved Gas Exchange Capacity in COPD Through Lung […]
Positive Airway Pressure Linked to Less Late-Night Heart Burn Problems
Positive airway pressure (PAP) treatment for obstructive sleep apnea (OSA) was linked to reduced respiratory symptoms and nocturnal gastroesophageal reflux (nGER), an Icelandic study found. After 2 years, full PAP users reported a decrease in both nGER (adjusted odds ratio [aOR] 0.58, 95% CI 0.40-0.86) and wheezing (aOR 0.56, 95% CI 0.35-0.88) compared with non-users, […]
What to Know About New Tools to Fight RSV
The tide may be turning on respiratory syncytial virus (RSV), a seasonal scourge that’s responsible for a substantial number of hospitalizations and deaths among older people and young children each year. In the span of just a few months, the FDA has approved two vaccines and a monoclonal antibody for use in specific populations with […]
Use of E-Cigs Alone Linked to Respiratory Symptoms
Use of e-cigarettes may be inherently associated with respiratory issues regardless of traditional cigarette or cannabis exposure, a prospective study found. Teenagers who reported using e-cigarettes in the previous 30 days subsequently reported an increased risk for shortness of breath (OR 1.78, 95% CI 1.23-2.57), wheezing (OR 1.81, 95% CI 1.28-2.56), and bronchitic symptoms (OR […]
Pre-COPD Current and Former Smokers Not in the Clear for Airway Disease
Whether they had respiratory symptoms or not, former and current smokers who didn’t meet criteria for chronic obstructive pulmonary disease (COPD) had similar declines in lung function and progression to COPD in subsequent years, the SPIROMICS II study found. Participants with symptomatic tobacco exposure and preserved spirometry (TEPS) experienced no significant difference in annual declines […]
FDA Panel Endorses mAb to Prevent RSV in Infants
An FDA advisory committee on Thursday gave strong backing to a monoclonal antibody against respiratory syncytial virus (RSV) to prevent lower respiratory tract disease (LRTD) in infants as well as in at-risk children up to 24 months of age. In a unanimous vote, all 21 members of the Antimicrobial Drugs Advisory Committee agreed that the […]
Breathing Support Type Matters for Preventing Extubation Failure in the PICU
Postextubation use of certain modes of noninvasive respiratory support was associated with fewer incidents of extubation failure in critically ill children, a meta-analysis found. Compared with conventional oxygen therapy, both continuous positive airway pressure (CPAP; OR 0.43, 95% credible interval [CrI] 0.17-1.0) and high-flow nasal cannula (HFNC; OR 0.64, 95% CrI 0.24-1.0) appeared more effective […]
Second RSV Vaccine Lands Approval for Older Adults
The FDA has approved a second respiratory syncytial virus (RSV) vaccine for preventing lower respiratory infections in adults 60 and over, Pfizer announced on Wednesday. Approval of the unadjuvanted, bivalent RSV prefusion F protein vaccine (Abrysvo) follows an endorsement in March from FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC). Advisors voted 7-4 in […]